Back to Hematology
Hematologyv1997Evidence-Based

Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria

Determines if immediate therapy for follicular lymphoma is needed by identifying high tumor burden patients requiring treatment rather than active surveillance

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
gelf result
—recommendation
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Positive if any one or more of the following criteria are present: tumor mass >7cm, ≥3 nodal sites >3cm, B symptoms, splenic enlargement below umbilical line, compression syndrome, serous effusion, leukemic phase >5.0×10⁹/L, granulocytes <1.0×10⁹/L, or platelets <100×10⁹/L

Clinical Pearls & Practice Notes

  • Originally developed by the Groupe d'Etude des Lymphomes Folliculaires to standardize treatment decisions in follicular lymphoma
  • Used to distinguish between patients requiring immediate treatment vs. active surveillance (watch and wait)
  • Should be used in conjunction with FLIPI score for comprehensive prognostic assessment
  • Recent studies suggest some discordance between GELF criteria and actual clinical treatment decisions
  • Criteria were developed in the pre-rituximab era but remain relevant in current practice
  • Consider patient comorbidities, age, and preferences when making final treatment decisions
  • Regular reassessment recommended during active surveillance period
  • Multidisciplinary team involvement recommended for complex cases

Evidence & Literature Citations

  1. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15(3):1110-1117. doi: 10.1200/JCO.1997.15.3.1110
  2. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. doi: 10.1182/blood-2003-12-4434
  3. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-522. doi: 10.1016/S0140-6736(03)14110-4

Score Interpretation Ranges

Low Tumor Burden≤ pts

Active surveillance appropriate

High Tumor Burden≤ pts

Immediate therapy recommended

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.